---
title: "Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294984192.md"
description: "Seres Therapeutics reported Q2 2026 revenue of $0.736M and net income of $4.581M, a significant turnaround from the prior year's loss. The company completed the sale of its VOWST business to SPN, generating near-term cash inflows. Operational restructuring included a 30% workforce reduction and pausing the SER-155 Phase 2 trial due to funding constraints. Pipeline progress continues with encouraging data for SER-155, SER-603, SER-428, and SER-147."
datetime: "2026-08-05T14:41:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294984192.md)
  - [en](https://longbridge.com/en/news/294984192.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294984192.md)
generator: "portal-rs"
---

# Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary

Seres Therapeutics, Inc. reported second-quarter 2026 results with revenue of $0.736M and net income attributable to common stockholders of $4.581M, or diluted EPS of $0.47, compared with no revenue, a net loss of $(19.855) M and diluted EPS of $(2.27) in the year-ago quarter.

**Financial Highlights**

-   Revenue was $0.736M for 2Q 2026, versus $0.0M in 2Q 2025.
-   Net income was $4.581M attributable to common stockholders for 2Q 2026, versus $(19.855) M in 2Q 2025.
-   Diluted EPS was $0.47 for 2Q 2026, versus $(2.27) in 2Q 2025.

**Business Highlights**

-   Revenue comprised grant revenue (CARB-X); there were no product sales. Management said milestone termination payments are expected to bridge near-term operations.
-   Pipeline progress: advancing SER-155, SER-603, SER-428 and SER-147 with encouraging Phase 1b and investigator-sponsored study data; SER-155 showed reductions in bloodstream infections (BSI) and responses in irEC.
-   Operational restructuring included roughly a 30% workforce reduction, a lease amendment to reduce space and costs, and a pause of the SER-155 Phase 2 trial pending funding.
-   Strategic transaction: the sale of the VOWST business to SPN has closed, with cross-license and milestone arrangements reshaping the portfolio and near-term cash inflows.
-   Clinical and translational readouts and publications supported the company’s microbiome- and barrier-integrity-focused approach, underpinning targeted development and partnership discussions.

Original SEC Filing: Seres Therapeutics, Inc. \[ MCRB \] - 10-Q - Aug. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MCRB.US](https://longbridge.com/en/quote/MCRB.US.md)

## Related News & Research

- [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md)
- [Johnson Controls announces dividend of R$ 0.10 per unit for 3Q 2026](https://longbridge.com/en/news/298924576.md)
- [Invitation Homes announces Q3 2026 dividend of R$ 0.21 per unit](https://longbridge.com/en/news/299044268.md)
- [ADM announces Q3 2026 dividend of R$ 0.22 per unit](https://longbridge.com/en/news/298917252.md)
- [BIOMM updates financial events calendar for 2026](https://longbridge.com/en/news/298958985.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**